Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vericel Corporation (NQ: VCEL )

43.74 -0.12 (-0.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vericel Corporation

Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
From Vericel Corporation
Via GlobeNewswire
Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
From Vericel Corporation
Via GlobeNewswire
5 medical stocks growing earnings by triple digits
There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning 
Via MarketBeat
Topics Economy
Exposures Economy
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
From Vericel Corporation
Via GlobeNewswire
Vericel Corp. (NASDAQ: VCEL) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
From Vericel Corporation
Via GlobeNewswire
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the Stephens Annual Investment Conference
From Vericel Corporation
Via GlobeNewswire
Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
From Vericel Corporation
Via GlobeNewswire
Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid
From Vericel Corporation
Via GlobeNewswire
Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the Morgan Stanley Global Healthcare Conference
From Vericel Corporation
Via GlobeNewswire
Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023
From Vericel Corporation
Via GlobeNewswire
Vericel Corp. (NASDAQ: VCEL) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023
From Vericel Corporation
Via GlobeNewswire
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023
From Vericel Corporation
Via GlobeNewswire
Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
From Vericel Corporation
Via GlobeNewswire
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
From MediWound Ltd.
Via GlobeNewswire
Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
From Vericel Corporation
Via GlobeNewswire
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END 
Via FinancialNewsMedia
Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference
From Vericel Corporation
Via GlobeNewswire
Vericel Reports Third Quarter 2022 Financial Results
From Vericel Corporation
Via GlobeNewswire
Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022
From Vericel Corporation
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.